126 related articles for article (PubMed ID: 17653791)
1. Distribution of Na+/I- symporter in thyroid cancers in an iodine-deficient population: an immunohistochemical study.
Mishra A; Pal L; Mishra SK
World J Surg; 2007 Sep; 31(9):1737-1742. PubMed ID: 17653791
[TBL] [Abstract][Full Text] [Related]
2. Iodine deficiency and thyroid nodular pathology--epidemiological and cancer characteristics in different populations: Portugal and South Africa.
Santos JE; Kalk WJ; Freitas M; Marques Carreira I; Castelo Branco M
BMC Res Notes; 2015 Jul; 8():284. PubMed ID: 26126625
[TBL] [Abstract][Full Text] [Related]
3. Iodine avidity in papillary and poorly differentiated thyroid cancer is predicted by immunohistochemical and molecular work-up.
Nilsson JN; Siikanen J; Condello V; Jatta K; Saini R; Hedman C; Ihre Lundgren C; Juhlin CC
Eur Thyroid J; 2023 Jul; 12(4):. PubMed ID: 37352166
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ALK-Signaling Overcomes STRN-ALK-Induced Downregulation of the Sodium Iodine Symporter and Restores Radioiodine Uptake in Thyroid Cells.
Nikitski AV; Condello V; Divakaran SS; Nikiforov YE
Thyroid; 2023 Apr; 33(4):464-473. PubMed ID: 36585857
[No Abstract] [Full Text] [Related]
5. Sodium iodide symporter immunolabelling as a predictor of clinical iodide uptake in canine thyroid carcinoma: A preliminary study.
Dark KV; Skinner OT; Kim DY; Karnia JJ; Mickelson MA; Maitz CA
Vet Comp Oncol; 2024 Jun; 22(2):239-244. PubMed ID: 38488259
[TBL] [Abstract][Full Text] [Related]
6. Do Molecular Profiles of Primary
Gomes-Lima CJ; Shobab L; Wu D; Ylli D; Bikas A; McCoy M; Feldman R; Lee W; Rao SN; Jensen K; Vasko V; Castro LC; Jonklaas J; Wartofsky L; Burman KD
Front Endocrinol (Lausanne); 2021; 12():623182. PubMed ID: 33716974
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells.
Zhang GQ; Xi C; Shen CT; Song HJ; Luo QY; Qiu ZL
Endocr Relat Cancer; 2023 Sep; 30(9):. PubMed ID: 37260320
[TBL] [Abstract][Full Text] [Related]
8. The Frequency of Differentiated Thyroid Cancer Recurrence in 2302 Patients With Excellent Response to Primary Therapy.
Pałyga I; Rumian M; Kosel A; Albrzykowski M; Krawczyk P; Kalwat A; Gąsior-Perczak D; Walczyk A; Kuchareczko A; Kopczyński J; Chrapek M; Góźdź S; Kowalska A
J Clin Endocrinol Metab; 2024 Jan; 109(2):e569-e578. PubMed ID: 37768152
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological features of differentiated thyroid carcinoma as predictors of the effects of radioactive iodine therapy.
Liu W; Jiang B; Xue J; Liu R; Wei Y; Li P
Ann Diagn Pathol; 2024 Apr; 69():152243. PubMed ID: 38128440
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Differentiated High-Grade Thyroid Carcinoma Among Well-Differentiated Tumors: A Systematic Review and Meta-Analysis.
Poma AM; Macerola E; Ghossein RA; Tallini G; Basolo F
Thyroid; 2024 Mar; 34(3):314-323. PubMed ID: 38115626
[No Abstract] [Full Text] [Related]
11. Global incidence and prevalence of differentiated thyroid cancer in childhood: systematic review and meta-analysis.
Moleti M; Aversa T; Crisafulli S; Trifirò G; Corica D; Pepe G; Cannavò L; Di Mauro M; Paola G; Fontana A; Calapai F; Cannavò S; Wasniewska M
Front Endocrinol (Lausanne); 2023; 14():1270518. PubMed ID: 37795368
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of the Na(+)/I(-) symporter protein in thyroid cancer and adjacent normal and nodular goiter tissues.
Wang S; Liang J; Lin Y; Yao R
Oncol Lett; 2013 Jan; 5(1):368-372. PubMed ID: 23255951
[TBL] [Abstract][Full Text] [Related]
13. Canine follicular cell and medullary thyroid carcinomas: Immunohistochemical characterization.
Jankovic J; Tièche E; Dettwiler M; Hahn K; Scheemaeker S; Kessler M; Daminet S; Rottenberg S; Campos M
Vet Pathol; 2023 Dec; ():3009858231217245. PubMed ID: 38098215
[TBL] [Abstract][Full Text] [Related]
14. The master role of polarized NIS expression in regulating iodine metabolism in the human body.
Lévay B; Lantos A; Sinkovics I; Slezák A; Tóth E; Dohán O
Arch Endocrinol Metab; 2023 Mar; 67(2):256-261. PubMed ID: 36913678
[TBL] [Abstract][Full Text] [Related]
15. The Na+/I- symporter (NIS): mechanism and medical impact.
Portulano C; Paroder-Belenitsky M; Carrasco N
Endocr Rev; 2014 Feb; 35(1):106-49. PubMed ID: 24311738
[TBL] [Abstract][Full Text] [Related]
16. Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies.
Aashiq M; Silverman DA; Na'ara S; Takahashi H; Amit M
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31533238
[TBL] [Abstract][Full Text] [Related]
17. Association between sodium iodide symporter and differentiated Thyroid cancer: a meta-analysis of 9 studies.
Zhang R; Wang H; Zhao J; Yao J; Shang H; Zhu H; Liao L; Dong J
Int J Clin Exp Med; 2015; 8(10):17986-94. PubMed ID: 26770393
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis and signaling pathways related to iodine-refractory differentiated thyroid cancer.
Zhao S; Zhao Y; Zhao Y; Wang G
Front Endocrinol (Lausanne); 2023; 14():1320044. PubMed ID: 38313845
[TBL] [Abstract][Full Text] [Related]
19. Sodium iodide symporter and the radioiodine treatment of thyroid carcinoma.
Chung JK; Youn HW; Kang JH; Lee HY; Kang KW
Nucl Med Mol Imaging; 2010 Apr; 44(1):4-14. PubMed ID: 24899932
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
